Medicinal cannabis

Michael Sassano, CEO at SOMAÍ Pharmaceuticals looks at what’s needed throughout Europe to help increase access to medicinal cannabis and the current state of pharmaceutical research in this area. The use of medicinal cannabis across much of the world is still in its infancy. Despite claims of a whole host of benefits, the clinical studies […]

An international study led by McMaster University scientists and published in The British Medical Journal show a minority of people living with chronic pain who try medical cannabis may experience important relief and the risk of side effects is typically small.  Data from 32 randomised controlled trials showed that use of non-inhaled medical cannabis versus placebo resulted in small […]

The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved a new indication for GW Pharmaceutical’s cannabidiol as an adjunctive treatment of seizures associated with tuberous sclerosis complex (TSC), for patients two years of age and older. GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an adjunctive therapy for seizures associated with […]

Botanical Holdings was founded in early 2020 with a focus on investing within the legal cannabis sector. There is now a substantial body of evidence to support the effectiveness of cannabis-based medicines in treating a range of conditions from epilepsy to chronic pain. More recently, attention has also turned to the potential of certain psychedelic […]

Medical cannabis is a growing market in Europe – but there is a lack of the usual regulatory framework intended to harmonise marketing of medicines and keep them safe. Arriello Director of Drug Safety Peter Kohut provides a guide to marketing cannabis products in the diverse European market. Medical cannabis has shown efficacy in trials […]